Display options
Cite
Roshi, Tandon VR, Mahajan A, et al. Comparative Efficacy and Safety of Clonazepam versus Nortriptyline in Restless Leg Syndrome among Forty Plus Women: A Prospective, Open-Label Randomized Study. J Midlife Health. 2019;10(4):197-203doi: 10.4103/jmh.JMH_26_18.
Roshi, Tandon, V. R., Mahajan, A., Sharma, S., & Khajuria, V. (2019). Comparative Efficacy and Safety of Clonazepam versus Nortriptyline in Restless Leg Syndrome among Forty Plus Women: A Prospective, Open-Label Randomized Study. Journal of mid-life health, 10(4), 197-203. https://doi.org/10.4103/jmh.JMH_26_18
Roshi, et al. "Comparative Efficacy and Safety of Clonazepam versus Nortriptyline in Restless Leg Syndrome among Forty Plus Women: A Prospective, Open-Label Randomized Study." Journal of mid-life health vol. 10,4 (2019): 197-203. doi: https://doi.org/10.4103/jmh.JMH_26_18
Roshi, Tandon VR, Mahajan A, Sharma S, Khajuria V. Comparative Efficacy and Safety of Clonazepam versus Nortriptyline in Restless Leg Syndrome among Forty Plus Women: A Prospective, Open-Label Randomized Study. J Midlife Health. 2019 Oct-Dec;10(4):197-203. doi: 10.4103/jmh.JMH_26_18. PMID: 31942156; PMCID: PMC6947720.
Copy Download .nbib Format: NLM
Share it on

J Midlife Health. 2019 Oct-Dec;10(4):197-203. doi: 10.4103/jmh.JMH_26_18.

Comparative Efficacy and Safety of Clonazepam versus Nortriptyline in Restless Leg Syndrome among Forty Plus Women: A Prospective, Open-Label Randomized Study.

Journal of mid-life health

Roshi, Vishal R Tandon, Annil Mahajan, Sudhaa Sharma, Vijay Khajuria

Affiliations

  1. Department of Pharmacology and Therapeutic, Government Medical College, Jammu, Jammu and Kashmir, India.
  2. Department of General Medicine, Government Medical College, Jammu, Jammu and Kashmir, India.
  3. Department of Obstetrics and Gynecology, Government Medical College, Jammu, Jammu and Kashmir, India.

PMID: 31942156 PMCID: PMC6947720 DOI: 10.4103/jmh.JMH_26_18

Abstract

AIMS AND OBJECTIVES: The aim of this study is to compare the effect of clonazepam and nortriptyline on rate, frequency, and severity of restless leg syndrome (RLS) in above 40 years women suffering from RLS.

MATERIALS AND METHODS: A prospective, randomized, open-label comparative study was conducted at a tertiary care teaching hospital for 1 year. Restless legs syndrome (RLS) diagnosis was based on four essential clinical criteria established by the International RLS Study Group in 2003. Patients were randomized into two groups. Group 1 received tablet clonazepam 0.5 mg bedtime orally daily. Group 2 received tablet nortriptyline 25 mg bedtime orally daily. The primary efficacy endpoints by the International Restless leg Syndrome Scale (IRLS) were evaluated at 0, 4, and 8 weeks. Adverse drug events and safety assessment for vital signs such as blood pressure, pulse, heart rate, waist circumference, and body mass index were compared between two groups.

RESULTS: Effect on mean IRLSS was statistically more in clonazepam group in comparison to nortriptyline group with comparable results at 8 weeks (

CONCLUSION: Both the drugs provided clinically and statistical significant effect on RLS when compared with their respective baselines. However, nortriptyline proved to be statistically better in improving the frequency of RLS in comparison to clonazepam, whereas the results were comparable with regard to rate and the severity of RLS on intergroup comparison. Both the drugs were well tolerated.

Copyright: © 2019 Journal of Mid-life Health.

Keywords: Plus forty age; restless leg syndrome; treatment drugs; women

Conflict of interest statement

There are no conflicts of interest.

References

  1. Neurotherapeutics. 2014 Jan;11(1):177-87 - PubMed
  2. J Gerontol A Biol Sci Med Sci. 2010 Feb;65(2):167-73 - PubMed
  3. Acta Neurol Scand. 1984 Jun;69(6):428-30 - PubMed
  4. Jpn J Psychiatry Neurol. 1992 Sep;46(3):727-32 - PubMed
  5. Ginecol Obstet Mex. 2007 May;75(5):286-92 - PubMed
  6. Neurology. 1998 Oct;51(4):1166-71 - PubMed
  7. Lancet. 2009 Oct 10;374(9697):1252-61 - PubMed
  8. Mov Disord. 2011 Jan;26(1):114-20 - PubMed
  9. Int J Geriatr Psychiatry. 2011 Dec;26(12):1252-9 - PubMed
  10. Can J Neurol Sci. 1986 Aug;13(3):245-7 - PubMed
  11. Biol Psychiatry. 2005 Sep 15;58(6):510-4 - PubMed
  12. Sleep Med. 2003 Mar;4(2):101-19 - PubMed
  13. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005454 - PubMed
  14. Nat Genet. 2007 Aug;39(8):1000-6 - PubMed
  15. Sleep Med. 2004 May;5(3):293-9 - PubMed
  16. Climacteric. 2008 Oct;11(5):422-8 - PubMed
  17. Eur Neuropsychopharmacol. 2001 Apr;11(2):153-61 - PubMed
  18. Diabetes Care. 2012 Dec;35(12):2451-8 - PubMed
  19. J Neurol Neurosurg Psychiatry. 1976 Mar;39(3):297-9 - PubMed
  20. J Gen Intern Med. 2009 Feb;24(2):178-88 - PubMed
  21. J Fam Pract. 2007 Feb;56(2 Suppl Pain):3-12 - PubMed
  22. Neurotherapeutics. 2012 Oct;9(4):776-90 - PubMed
  23. Mov Disord. 2007 Jul 30;22(10):1451-6 - PubMed
  24. Mov Disord. 2014 Jul;29(8):1044-52 - PubMed
  25. Mov Disord. 1995 Sep;10(5):634-42 - PubMed
  26. Cochrane Database Syst Rev. 2012 May 16;(5):CD009486 - PubMed
  27. Gen Hosp Psychiatry. 2015 Jan-Feb;37(1):36-9 - PubMed
  28. Am J Med. 2013 Mar;126(3):220-7, 227.e1-2 - PubMed
  29. J Neurol Neurosurg Psychiatry. 1987 Dec;50(12):1679-81 - PubMed
  30. Ann Pharmacother. 2011 Dec;45(12):1483-90 - PubMed
  31. Sleep. 2008 Jul;31(7):979-90 - PubMed
  32. Sleep Med. 2010 Jan;11(1):82-6 - PubMed
  33. Sleep Med. 2007 Dec;9(1):88-93 - PubMed
  34. Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):522-6 - PubMed

Publication Types